ANGELA STERLING: Open Payments
NPI 1578720231 · JACKSON, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,025 in 49 payments from 14 companies in 2025. Trend: 2023 $852 · 2024 $900 · 2025 $1,025
Food & beverage: $1,025
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 17 | $329 |
| AstraZeneca Pharmaceuticals LP | 2 | $145 |
| Merck Sharp & Dohme LLC | 4 | $91 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $76 |
| SCPHARMACEUTICALS INC. | 4 | $74 |
| E.R. Squibb & Sons, L.L.C. | 3 | $56 |
| Esperion Therapeutics, Inc. | 3 | $54 |
| Medtronic, Inc. | 1 | $44 |
| Alnylam Pharmaceuticals Inc. | 2 | $36 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $32 |
Products named: LEQVIO, LOKELMA, Kerendia, FUROSCIX, VERQUVO, NEXLETOL, ELIQUIS, SYMPLICITY G3.
Industry payments across MS — which companies pay providers there.
